Graham J Mann

Summary

Affiliation: University of Sydney
Country: Australia

Publications

  1. pmc Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer
    Aaron G Lewis
    Department of Cancer Genetics, Queensland Institute of Medical Research, Brisbane, Queensland, Australia
    Breast Cancer Res 7:R1005-16. 2005
  2. pmc Variation in the RAD51 gene and familial breast cancer
    Felicity Lose
    Cancer and Cell Biology Division, Queensland Institute of Medical Research, Brisbane, Queensland, Australia
    Breast Cancer Res 8:R26. 2006
  3. pmc BCoR-L1 variation and breast cancer
    Felicity Lose
    Cancer and Cell Biology Division, Queensland Institute of Medical Research, 300 Herston Road, Brisbane, Queensland, Australia, 4006
    Breast Cancer Res 9:R54. 2007
  4. pmc Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource
    Graham J Mann
    Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales, Australia
    Breast Cancer Res 8:R12. 2006
  5. pmc p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors
    Stuart J Gallagher
    Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead NSW 2145, Australia
    Neoplasia 10:1231-9. 2008
  6. doi request reprint Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma
    Georgina V Long
    Melanoma Institute Australia, 40 Rocklands Rd, North Sydney, New South Wales, 2060, Australia
    J Clin Oncol 29:1239-46. 2011
  7. doi request reprint IGFBP7 is not required for B-RAF-induced melanocyte senescence
    Lyndee L Scurr
    Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia
    Cell 141:717-27. 2010
  8. doi request reprint Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A
    Heather A McKenzie
    Westmead Institute for Cancer Research and Melanoma Institute of Australia, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead NSW 2145, Australia
    Hum Mutat 31:692-701. 2010
  9. ncbi request reprint Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer
    Mark Wong
    Westmead Institute for Cancer Research Westmead Millennium Institute, Department of Translational Oncology, Westmead, Australia
    J Clin Oncol 24:2448-55. 2006
  10. doi request reprint BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma
    Graham J Mann
    1 The University of Sydney at Westmead Millennium Institute, Westmead, New South Wales, Australia 2 Melanoma Institute Australia formerly the Sydney Melanoma Unit, Sydney, New South Wales, Australia
    J Invest Dermatol 133:509-17. 2013

Detail Information

Publications40

  1. pmc Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer
    Aaron G Lewis
    Department of Cancer Genetics, Queensland Institute of Medical Research, Brisbane, Queensland, Australia
    Breast Cancer Res 7:R1005-16. 2005
    ..We hypothesized that germline mutations in FANCD2, BRIP1/BACH1, LMO4 and SFN may account for some of the unexplained multiple-case breast cancer families...
  2. pmc Variation in the RAD51 gene and familial breast cancer
    Felicity Lose
    Cancer and Cell Biology Division, Queensland Institute of Medical Research, Brisbane, Queensland, Australia
    Breast Cancer Res 8:R26. 2006
    ..Few studies have investigated the role of coding region variation in the RAD51 gene in familial breast cancer, with only one coding region variant--exon 6 c.449G>A (p.R150Q)--reported to date...
  3. pmc BCoR-L1 variation and breast cancer
    Felicity Lose
    Cancer and Cell Biology Division, Queensland Institute of Medical Research, 300 Herston Road, Brisbane, Queensland, Australia, 4006
    Breast Cancer Res 9:R54. 2007
    ..BCoR-L1 is located on the X chromosome and is subject to X inactivation...
  4. pmc Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource
    Graham J Mann
    Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales, Australia
    Breast Cancer Res 8:R12. 2006
    ....
  5. pmc p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors
    Stuart J Gallagher
    Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead NSW 2145, Australia
    Neoplasia 10:1231-9. 2008
    ..This study shows that high expression of p16(INK4a) or the absence of activated B-RAF correlates with in vivo response of melanoma to cytotoxic drugs...
  6. doi request reprint Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma
    Georgina V Long
    Melanoma Institute Australia, 40 Rocklands Rd, North Sydney, New South Wales, 2060, Australia
    J Clin Oncol 29:1239-46. 2011
    ..To assess the frequency and type of oncogenic BRAF mutations in metastatic melanoma and correlate BRAF status with clinicopathologic features and outcome...
  7. doi request reprint IGFBP7 is not required for B-RAF-induced melanocyte senescence
    Lyndee L Scurr
    Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia
    Cell 141:717-27. 2010
    ..Therefore, we conclude that the secreted protein IGFBP7 is dispensable for B-RAF(V600E)-induced senescence in human melanocytes...
  8. doi request reprint Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A
    Heather A McKenzie
    Westmead Institute for Cancer Research and Melanoma Institute of Australia, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead NSW 2145, Australia
    Hum Mutat 31:692-701. 2010
    ..The ability to determine variant functional activity accurately would identify disease-associated mutations and facilitate effective genetic counselling of individuals at high risk of melanoma...
  9. ncbi request reprint Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer
    Mark Wong
    Westmead Institute for Cancer Research Westmead Millennium Institute, Department of Translational Oncology, Westmead, Australia
    J Clin Oncol 24:2448-55. 2006
    ..The aim of this study was to evaluate pretreatment clinical features, genotype and functional indicators of drug clearance as predictors of vinorelbine clearance, and myelotoxicity that could inform dosage optimization...
  10. doi request reprint BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma
    Graham J Mann
    1 The University of Sydney at Westmead Millennium Institute, Westmead, New South Wales, Australia 2 Melanoma Institute Australia formerly the Sydney Melanoma Unit, Sydney, New South Wales, Australia
    J Invest Dermatol 133:509-17. 2013
    ..We conclude that the presence of BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in melanoma patients with macroscopic stage III disease...
  11. pmc The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a
    Therese M Becker
    Westmead Institute for Cancer Research, University of Sydney, Westmead Millennium Institute and Westmead Hospital, Australia
    Mol Cancer 8:4. 2009
    ..To identify such functions we conducted a yeast-two-hybrid screen for novel p16INK4a binding partners...
  12. ncbi request reprint Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions
    James O Indsto
    Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead, NSW, Australia
    J Cutan Pathol 34:448-55. 2007
    ..Germline DNA from members of 111 multiple-case melanoma families, representing a range of known (CDKN2A) and unknown predisposing gene defects, was analyzed for germline BRAF mutations, but none was found...
  13. pmc Oncogenic B-RAF(V600E) signaling induces the T-Box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion
    Suzanah C Boyd
    University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales, Australia
    J Invest Dermatol 133:1269-77. 2013
    ..We propose that this B-RAF/Tbx3/E-cadherin pathway has a critical role in promoting the metastasis of B-RAF-mutant melanomas...
  14. doi request reprint Review and cross-validation of gene expression signatures and melanoma prognosis
    Sarah Jane Schramm
    Sydney Medical School, The University of Sydney at Westmead Millennium Institute, Sydney, New South Wales, Australia
    J Invest Dermatol 132:274-83. 2012
    ....
  15. doi request reprint Genetic testing for melanoma risk: a prospective cohort study of uptake and outcomes among Australian families
    Nadine A Kasparian
    School of Women s and Children s Health, Faculty of Medicine, University of New South Wales, Kensington, New South Wales, Australia
    Genet Med 11:265-78. 2009
    ..The aim of this prospective cohort study was to examine uptake and psychological, behavioral, and cognitive outcomes of genetic testing for melanoma risk among individuals with a known family-specific CDKN2A mutation...
  16. doi request reprint An extended antibody microarray for surface profiling metastatic melanoma
    Kimberley L Kaufman
    School of Molecular and Microbial Biosciences, The University of Sydney, NSW, Australia
    J Immunol Methods 358:23-34. 2010
    ....
  17. doi request reprint Familial concordance of breast cancer pathology as an indicator of genotype in multiple-case families
    Rosemary L Balleine
    Translational Oncology, Sydney West Area Health Service, Sydney, Australia
    Genes Chromosomes Cancer 49:1082-94. 2010
    ..237). The pattern of breast cancer pathology concordance amongst family members may assist the investigation of breast cancer susceptibility in multiple case families...
  18. ncbi request reprint Better the devil you know? High-risk individuals' anticipated psychological responses to genetic testing for melanoma susceptibility
    Nadine A Kasparian
    Medical Psychology Research Unit, School of Psychology, University of Sydney, Sydney, Australia
    J Genet Couns 15:433-47. 2006
    ..The present study aimed to explore anticipated emotional, behavioral, cognitive, and familial responses to hypothetical genetic testing for melanoma susceptibility...
  19. ncbi request reprint Anticipated uptake of genetic testing for familial melanoma in an Australian sample: An exploratory study
    Nadine A Kasparian
    Medical Psychology Research Unit, School of Psychology, University of Sydney, Sydney, Australia
    Psychooncology 16:69-78. 2007
    ..The potential role of genetic testing in families with an inherited pattern of melanoma is a complex issue, and yet limited data exist on perceptions of predictive genetic testing for mutations among individuals at high risk of melanoma...
  20. ncbi request reprint eMelanoBase: an online locus-specific variant database for familial melanoma
    David C Y Fung
    Westmead Institute for Cancer Research, University of Sydney, Westmead Millennium Institute, Westmead, NSW, Australia
    Hum Mutat 21:2-7. 2003
    ..The object-relational database schema was deduced using functional dependency analysis. We hereby present our first functional prototype of eMelanoBase. The service is accessible via the URL www.wmi.usyd.edu.au:8080/melanoma.html...
  21. ncbi request reprint Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer
    Mark Wong
    Westmead Institute for Cancer Research, Department of Nuclear Medicine, Westmead Hospital, University of Sydney, Camperdown, Australia
    Clin Pharmacol Ther 77:33-42. 2005
    ....
  22. ncbi request reprint Frequent loss of heterozygosity targeting the inactive X chromosome in melanoma
    James O Indsto
    Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead, New South Wales, Australia
    Clin Cancer Res 9:6476-82. 2003
    ..Analysis of copy number in this region by quantitative PCR showed restoration to disomy and, in one case, trisomy at AR...
  23. ncbi request reprint The melanoma-associated 24 base pair duplication in p16INK4a is functionally impaired
    Therese M Becker
    Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, New South Wales, Australia
    Int J Cancer 117:569-73. 2005
    ..We also show that the cell cycle-regulatory defect of the p16INK4a duplication mutant was associated with decreased inhibition of pRb phosphorylation even though it retained significant binding to CDK4...
  24. ncbi request reprint Is there a role for genetic testing in patients with melanoma?
    Richard F Kefford
    Department of Medicine, Melanoma Genetics Research, Westmead Millennium Institute for Cancer Research, University of Sydney at Westmead Hospital, Westmead, NSW, 2145, Australia
    Curr Opin Oncol 15:157-61. 2003
    ..Rather than singling out those deemed to be at high risk because of family history, all patients carrying risk factors for cutaneous melanoma should be subject to stringent programs of sun protection and skin surveillance...
  25. doi request reprint Melanoma prognosis: a REMARK-based systematic review and bioinformatic analysis of immunohistochemical and gene microarray studies
    Sarah Jane Schramm
    Melanoma Genomics and Genetic Epidemiology Research Group, The University of Sydney at Westmead Millennium Institute, Westmead, NSW, Australia
    Mol Cancer Ther 10:1520-8. 2011
    ....
  26. pmc Localization of a novel melanoma susceptibility locus to 1p22
    Elizabeth Gillanders
    Cancer Genetics Branch, National Human Genome Research Institute, Bethesda, MD
    Am J Hum Genet 73:301-13. 2003
    ..43, was obtained at D1S2779 and occurred when the 15 families with the earliest ages at onset were included. These data provide significant evidence of a novel susceptibility gene for CMM located within chromosome band 1p22...
  27. ncbi request reprint Geographical variation in the penetrance of CDKN2A mutations for melanoma
    D Timothy Bishop
    Genetic Epidemiology Division, Cancer Research UK Clinical Centre, St James s University Hospital, Leeds, UK
    J Natl Cancer Inst 94:894-903. 2002
    ..We examined the penetrance of such mutations using data from eight groups from Europe, Australia and the United States that are part of The Melanoma Genetics Consortium...
  28. pmc Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents
    Alisa M Goldstein
    Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, Maryland 20892 7236, USA
    J Med Genet 44:99-106. 2007
    ....
  29. ncbi request reprint Intronic sequence variants of the CDKN2A gene in melanoma pedigrees
    Mark Harland
    Genetic Epidemiology Division, Cancer Research UK Clinical Centre, St James s University Hospital, Leeds, England
    Genes Chromosomes Cancer 43:128-36. 2005
    ..IVS1 + 1104 was shown to result in the aberrant splicing of both p16(INK4a) and p14(ARF) mRNA. Overall, however, the proportion of English melanoma families with these variants is small...
  30. pmc Common sequence variants on 20q11.22 confer melanoma susceptibility
    Kevin M Brown
    Integrated Cancer Genomics Division, The Translational Genomics Research Institute, Phoenix, Arizona 85028, USA
    Nat Genet 40:838-40. 2008
    ..The per allele odds ratio was 1.75 (1.53, 2.01), with evidence for stronger association in early-onset cases...
  31. ncbi request reprint High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL
    Alisa M Goldstein
    Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, Maryland 20892 7236, USA
    Cancer Res 66:9818-28. 2006
    ..This GenoMEL study provides the most extensive characterization of mutations in high-risk melanoma susceptibility genes in families with three or more melanoma patients yet available...
  32. ncbi request reprint Mutation analysis of five candidate genes in familial breast cancer
    Anna Marsh
    Cancer and Cell Biology, Queensland Institute of Medical Research, c o RBH Post Office, Herston, Brisbane, QLD, 4029, Australia
    Breast Cancer Res Treat 105:377-89. 2007
    ..Although we identified many novel variants, we found no evidence that highly penetrant germline mutations in these five genes contribute to familial breast cancer susceptibility...
  33. pmc A genome wide linkage search for breast cancer susceptibility genes
    Paula Smith
    CR UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
    Genes Chromosomes Cancer 45:646-55. 2006
    ..They also indicate that no single gene is likely to account for a large fraction of the familial aggregation of breast cancer that is not due to mutations in BRCA1 or BRCA2...
  34. ncbi request reprint High- and average-risk individuals' beliefs about, and perceptions of, malignant melanoma: an Australian perspective
    Nadine A Kasparian
    Medical Psychology Research Unit, School of Psychology, University of Sydney, Australia
    Psychooncology 17:270-9. 2008
    ..The data provide preliminary evidence for the importance of identifying misconceptions that may impede informed decision-making about genetic testing for melanoma risk...
  35. ncbi request reprint Dominant negative ATM mutations in breast cancer families
    Georgia Chenevix-Trench
    Queensland Institute of Medical Research, Brisbane, Australia
    J Natl Cancer Inst 94:205-15. 2002
    ..We examined these two ATM mutations in a population-based, case-control series of breast cancer families and multiple-case breast cancer families...
  36. ncbi request reprint Is MSH2 a breast cancer susceptibility gene?
    Ee Ming Wong
    Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Melbourne 3010, Australia
    Fam Cancer 7:151-5. 2008
    ..Extensive screening of 59 multiple-case breast cancer families did not identify any coding region mutations or larger genomic alterations in MSH2 that might implicate MSH2 as a breast cancer susceptibility gene...
  37. pmc A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL)
    Mark Harland
    Division of Epidemiology and Biostatistics, Leeds Institute of Molecular Medicine, Cancer Research UK Cancer Centre at Leeds, St James s University Hospital, Leeds, UK
    Eur J Cancer 44:1269-74. 2008
    ..The relatively low rate of CDKN2A mutation detection is not due to failure to detect mutations and implies the existence of other high penetrance melanoma susceptibility genes...
  38. ncbi request reprint EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer
    Jennifer L Clancy
    Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW 2010, Australia
    Oncogene 22:5070-81. 2003
    ..These results demonstrate that AI at the EDD locus is common in a diversity of carcinomas and that the EDD gene is frequently overexpressed in breast and ovarian cancer, implying a potential role in cancer progression...
  39. ncbi request reprint Deletion mapping suggests that the 1p22 melanoma susceptibility gene is a tumor suppressor localized to a 9-Mb interval
    Graeme J Walker
    Human Genetics Laboratory, Queensland Institute of Medical Research, Brisbane, Queensland, Australia
    Genes Chromosomes Cancer 41:56-64. 2004
    ....
  40. ncbi request reprint Expression analysis of a tyrosinase promoter sequence in zebrafish
    Esther Camp
    Department of Molecular Biosciences, University of Adelaide, SA, Australia
    Pigment Cell Res 16:117-26. 2003
    ....